Publication: Myeloid CD11c+ S100+ dendritic cells express
indoleamine 2,3-dioxygenase at the inflammatory
border to invasive lower lip squamous cell carcinoma
Authors
Kuales, Melanie Alice ; Wenzel, Jörg ; Schmid-Wendtner, Monika-Hildegard ; Bieber, Thomas ; Bubnoff, Dagmar von
item.page.secondaryauthor
item.page.director
Publisher
Editores F. Hernandez y Juan F. Madrid. Murcia, Universidad de Murcia, Departamento de Biologia Celular e Histologia
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The prevalence of squamous cell carcinoma
of the lower lip (SCC-LL) is increasing worlwide. The
expression of the enzyme indoleamine 2,3-dioxygenase
(IDO) by antigen-presenting cells and/or tumor cells
leads to tumor escape by inhibiting T cell-mediated
rejection responses. The aim of this study was to
determine the expression of IDO in SCC-LL. IDOexpression
was analyzed in 47 SCC-LL, together with
the expression of markers of T-cells (CD3), myeloid
DCs (S100, CD11c), macrophages (CD68, CD11c),
Langerhans cells (CD1a, Langerin (CD207)),
plasmacytoid DCs (CD123), and regulatory T cells
(Foxp3) by immunohistochemistry and immunofluorescence
analysis. Twelve specimens out of 47 LLSCCs
contained cells that expressed IDO. IDO-positivity
was strongly associated with the intensity of the cancerassociated
infiltrate (P=0.0007). IDO-positive cells are
located right along the border between the developing
tumor and the inflammatory infiltrate. Immunofluorescence
stainings showed that CD11c+S100+CD68-
dendritic cells (DCs) express IDO in SCC-LL. IDO
expression in LL-SCC may aid immune escape and
chronic inflammation to promote cancer progression.
Inhibition of IDO might be a therapeutic strategy to
increase the anti-tumor immune response in SCC-LL.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.